Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mesalazin (ausschl. Dafo RSU + KLI), ATC A07EC02 für die Zeit 01.06.26 - 31.05.28 (zzgl. V.-Option 1x12 Mon)

Section 130a, Paragraph 8, SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of statutory health insurance. In view of the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the above-mentioned active substance Mesalazin (exclusively in the dosage forms RSU + KLI), ATC A07EC02, DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until the entry into force of new medicines discount contracts. A discount contract under the authorisation model for the above-mentioned active substance will come into force for the first time on 01.06.2026 and will end on 31.05.2028 (plus extension option 1x12 months). It will end automatically, regardless of this, with the entry into force of the exclusive contract.